Kyverna Therapeutics

08/31/2026

For people living with (MG), every step forward in research matters.

Dr. Ali Habib, a neurologist at University of California, Irvine, shares why clinical trial participation is critical to advancing research and new treatment options for the MG community.

At Kyverna, we’re focused on continuing the momentum of progress for the generalized MG community. Learn more about our gMG clinical trial at: https://www.myastheniagravistrials.com/

08/19/2026

Living with (SPS) means facing muscle stiffness and frequent painful spasms. Today, there are no FDA-approved therapies for this rare, debilitating neurologic autoimmune disease.

Mark knows this reality firsthand. In his own words, he shares what it’s really like living with SPS.

It’s people like Mark who fuel our motivation each day as we work to deliver the potential first FDA-approved treatment for SPS.

06/17/2026

As we recognize and , we’re grateful to Bryan Bosch, leader of the Myasthenia Gravis Association's LGBTQIA+ MG support group, for highlighting the importance of creating spaces where individuals can show up authentically and find support through shared lived experiences.

Progress is fueled not only by scientific innovation, but also by the strength of community. We’re inspired by the MG community every day!

Support groups can help us find connection, community and belonging. Find (MG) support groups here: https://mgassociation.org/support-groups

06/15/2026

06/11/2026

Kyverna is proud to be a sponsor of The Stiff Person Research Foundation’s 2026 Patient Symposium, where we will partner with the Foundation to deliver the “Your Voice, Your Impact” initiative. The goal is simple but powerful: to help people living with stiff person syndrome share their stories and better express how SPS affects their daily lives with those around them.

“We believe every SPS story has the power to create understanding, inspire action, and drive meaningful change, and we’re grateful to have Kyverna’s partnership in bringing this vision to life."

- Neil Mathis, Head of Communications, The Stiff Person Syndrome Research Foundation

We're looking forward to gathering with the community at ! To learn more or attend virtually, visit: https://www.stiffperson.org/2026symposium

06/05/2026

Kyverna’s Sunetra Biswas had the pleasure of recently attending Myasthenia Gravis Foundation of America, Inc. (MGFA)’s San Diego Health Fair, sharing information about our Phase 3 CAR T-cell therapy clinical trial in generalized myasthenia gravis (gMG), KYSA-6.

As we kick off MG Awareness Month, we’re grateful to the MGFA for the opportunity to connect with people living with MG and their caregivers, and to support this incredible community.

Learn more by visiting: https://www.myastheniagravistrials.com/

05/21/2026

This , we’re honored to spotlight this video of Tara Zier, CEO of The Stiff Person Syndrome Research Foundation, and her perspective on the mental health impact of .

SPS is a rare, progressive disease and the need for an approved treatment option is urgent. Like many rare diseases, SPS affects more than physical health; it can also impact emotional well-being, relationships, and daily life.

At Kyverna, we’re proud to help amplify voices that foster connection, awareness, and hope. Our commitment to advancing innovative CAR T therapies is driven by the urgent needs of people living with SPS and their families.

Explore resources from the SPSRF here: https://www.stiffperson.org/sps-resources

04/21/2026

We’re very pleased to share positive primary analysis results from our registrational trial in : https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-presents-registrational-trial-primary-analysis-miv-cel

The findings, featured as a late-breaking oral presentation at the American Academy of Neurology (AAN)’s , underscore the potential for our investigational CAR T-cell therapy, miv-cel, to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for this rare, progressive disease.

04/20/2026

We’re pleased to share positive longer-term follow-up Phase 2 data for our investigational CAR T-cell therapy, miv-cel, in generalized : https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-presents-longer-term-phase-2-data-miv-cel-generalized

The data, featured as an oral presentation at the American Academy of Neurology’s , reinforce miv-cel’s potential to set a new clinical standard in gMG. For people navigating , progress matters. We’re grateful to the trial participants and clinical investigators who make it possible.

04/15/2026

Congratulations to the Myasthenia Gravis Foundation of America, Inc. on another successful National Patient Conference! We are grateful for the opportunity to engage with the community of caregivers and patients like Kathy Timothy who shared why this event is so valuable.

To learn more about our KYSA-6 CAR T clinical trial in gMG, visit: myastheniagravistrials.com